ChemotherapyFDA-approvedSecond-line
Taxotere
Generic name: docetaxel
How it works
Interferes with cell division, causing cancer cells to die.
Cancer types
Prostate Cancer— All patients
Efficacy
In clinical trials, around 50% of patients achieved an objective response, with median overall survival of approximately 18 months.
Side effects
Severe
This treatment carries a higher risk of serious side effects. Close medical monitoring is required throughout treatment.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Comparing Treatments for Advanced Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| Testing Combination Therapy for Advanced Prostate Cancer | Prostate Cancer | phase-3 | — | Source → |
| Abiraterone and Antiandrogen Therapy for Metastatic Prostate Cancer | Prostate Cancer | phase-2 | — | Source → |
| New Treatment Combination Shows Promise for HER2 Positive Breast Cancer | Breast Cancer | phase-3 | Overall survival was longer in the pyrotinib group (hazard ratio 0.64 (95% confidence interval (CI) 0.46 to 0.89); nominal one-sided P=0.004). | Source → |
| Evaluating Nivolumab and Docetaxel for Advanced Lung Cancer | Lung Cancer | preclinical | — | Source → |
| Study of a New Medicine for Lung Cancer | Lung Cancer | phase-3 | — | Source → |
| New Insights into Prostate Cancer Treatment Options | Prostate Cancer | meta-analysis | Darolutamide + docetaxel + ADT showed significant benefit over docetaxel + ADT, ADT and standard-nonsteroidal-antiandrogen + ADT in all analyses. | Source → |
| Eugenol Derivatives Enhance Chemotherapy Effectiveness in Prostate Cancer Cells | Prostate Cancer | lab-study | — | Source → |
| Chemotherapy Combination Affects Lung Cancer Cells in Lab Experiments | Lung Cancer | lab-study | — | Source → |
| Hospitalization Risks Vary for Prostate Cancer Patients on Different Treatments | Prostate Cancer | observational | — | Source → |
| Early Docetaxel and Enzalutamide for Prostate Cancer: New Insights | Prostate Cancer | phase-3 | Among those assigned no enzalutamide, OS was longer with the planned use of early docetaxel (HR 0.90, 95% CI 0.82-0.98), especially in high-volume disease. | Source → |
| METTL14's Role in Lung Cancer Progression and Docetaxel Resistance | Lung Cancer | lab-study | — | Source → |
| Atezolizumab Compared to Docetaxel in Lung Cancer Treatment | Lung Cancer | meta-analysis | Atezolizumab had better efficacy than docetaxel for overall survival (HR: 0.77, 95% CI: 0.73 to 0.81). | Source → |
| New Nanoparticle Delivery System Shows Promise for Breast Cancer Treatment | Breast Cancer | lab-study | The cRGD-HA-CDU@DTX system exhibited a 64.12% tumor growth reduction. | Source → |
| Real-world safety of docetaxel for lung cancer treatment | Lung Cancer | observational | — | Source → |
| GRIM-19's Role in Prostate Cancer Treatment | Prostate Cancer | lab-study | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.